D000072078

10 trials

Sponsors

Kaneta Tomohiro, Sugita Toshiki, Toda Kazuma, Watabe Tadashi, Nakamoto Yuji

Conditions

Alzheimer-type dementia Alzheimer-type dementiaConnective tissue disease-associated interstitial lung disease (CTD-ILD) Connective tissue disease-associated interstitial lung disease, Progressive pulmonary fibrosis, Rheumatoid arthritis, Systemic sclerosis, Idiopathic inflammatory myopathies, Sjogren's disease, Systemic lupus erythematosus, Mixed connective tissue disease, ANCA-associated vasculitisGlioblastoma, IDH wild-type Glioblastoma, 18F-Fluciclovine PET, MRIHead and neck squamous cell carcinoma Head and neck squamous cell carcinomaLung cancer LAT1 PET diagnosisMalignant tumor malignant tumorMyocarditis-group diseases and Non-myocarditis-group diseases VLA-4-targeted PET diagnosis of Lymphocytic MyocarditisNon-small cell lung cancer lung cancer

Early Phase 1

Clinical [F18]SNFT-1 PET Research

RecruitingJPRN-jRCTs021260016

Kaneta TomohiroAlzheimer-type dementia Alzheimer-type dementia

Start: 2026-06-09Target: 10Updated: 2026-06-29

Phase 1

Safety evaluation of PET probe F18-NKO-035

Active, not recruitingJPRN-jRCTs051190057

Watabe TadashiNormal healthy volunteer LAT1 PET diagnosis

Start: 2019-11-14Target: 4Updated: 2026-06-29

Safety evaluation of VLA-4-targeted PET probe

Active, not recruitingJPRN-jRCTs051250020

Watabe TadashiNormal healthy volunteer VLA-4 PET diagnosis

Start: 2025-05-12Target: 3Updated: 2026-06-29

Phase 2

Radiotherapy planning using PET-CT in the head and neck cancer patient

Active, not recruitingJPRN-jRCTs032180106

Toda KazumaHead and neck squamous cell carcinoma Head and neck squamous cell carcinoma

Start: 2016-08-30Target: 40Updated: 2026-06-29

Usefulness evaluation of PET probe F18-NKO-035

Active, not recruitingJPRN-jRCTs051200075

Watabe TadashiLung cancer LAT1 PET diagnosis

Start: 2020-10-27Target: 12Updated: 2026-06-29

Evaluation of treatment response for immune checkpoint inhibitors using [ 18F]F-AraG PET/CT

RecruitingJPRN-jRCTs051240253

Nakamoto YujiMalignant tumor malignant tumor

Start: 2025-02-04Target: 153Updated: 2026-06-29

Exploratory Study of Fluciclovine PET/MRI for Treatment Response in Newly Diagnosed Glioblastoma

RecruitingJPRN-jRCTs051250254

Sasayama TakashiGlioblastoma, IDH wild-type Glioblastoma, 18F-Fluciclovine PET, MRI

Start: 2026-04-15Target: 20Updated: 2026-06-29

Utility evaluation of VLA-4-targeted PET probe

RecruitingJPRN-jRCTs051260088

Matsuoka KenMyocarditis-group diseases and Non-myocarditis-group diseases VLA-4-targeted PET diagnosis of Lymphocytic Myocarditis

Start: 2026-06-22Target: 50Updated: 2026-06-29

[18F] Fibroblast Activation Protein Inhibitor PET/CT for Evaluation of Lung Fibrosis Activity in Connective Tissue Disease-Associated Interstitial Lung Disease

RecruitingJPRN-jRCTs031260239

Sugita ToshikiConnective tissue disease-associated interstitial lung disease (CTD-ILD) Connective tissue disease-associated interstitial lung disease, Progressive pulmonary fibrosis, Rheumatoid arthritis, Systemic sclerosis, Idiopathic inflammatory myopathies, Sjogren's disease, Systemic lupus erythematosus, Mixed connective tissue disease, ANCA-associated vasculitis

Start: 2026-06-22Target: 50Updated: 2026-06-29

Unknown Phase

Evaluation of treatment response for immune checkpoint inhibitors in non-small cell lung cancer patients using [18F]F-AraG PET/CT

Active, not recruitingJPRN-jRCTs051220109

Nakamoto YujiNon-small cell lung cancer lung cancer

Start: 2022-10-26Target: 60Updated: 2026-06-29